AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26946725 — intervention group
Group type: COMPARATOR
Intervention: Simple oral glucocorticoid (methylprednisolone 24 mg daily, tapering down over 6 weeks)
Number of subjects: 81
Study 23712600 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin/laropiprant (1000/20 mg daily for 4 weeks and 2000/40 mg daily thereafter)
Number of subjects: 63
Study 23712600 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 22920599 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized biventricular pacing
Number of subjects: 30
Study 22920599 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing
Number of subjects: 30
Study 22920599 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 30
Study 21504975 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 14
Study 21504975 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 14
Study 17913310 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage trivalent influenza vaccine (60 microg of HA for each component)
Number of subjects: 0
Study 17913310 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccine (15 microg of HA for each component)
Number of subjects: 0
Study 16275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI
Number of subjects: 106
Study 16275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with no viable myocardium
Number of subjects: 106
Study 16275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with viability
Number of subjects: 106
Study 16275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with color kinesis on day 1 and 1, 3, and 6 months after AMI for patients with only diastolic wall‐motion abnormalities
Number of subjects: 106
Study 12133142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminders
Number of subjects: 1641
Study 12133142 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1641
Study 11910662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 5 mg dydrogesterone
Number of subjects: 151
Study 11910662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol + 10 mg dydrogesterone
Number of subjects: 151
Study 7772369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 40
Study 7772369 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 40
Study 2298969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cyclosporine administered three times weekly for 4 weeks
Number of subjects: 6
Study 2298969 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 6
Study 2298969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cyclosporine
Number of subjects: 6
Study 6110570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin (250 microgram/hour) for 120 minutes
Number of subjects: 9
Study 6110570 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 6110570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin (in vitro)
Number of subjects: 9
Study 6110570 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (in vitro)
Number of subjects: 9
Study 6110570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin
Number of subjects: 9
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: both ceftazidime/avibactam and ceftolozane/tazobactam
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: neither ceftazidime/avibactam nor ceftolozane/tazobactam
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam only
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam only
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: XDR isolates
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftazidime/avibactam and ceftolozane/tazobactam
Number of subjects: 205
Study 31504587 — intervention group
Group type: EXPERIMENTAL
Intervention: non-susceptibility
Number of subjects: 205
Study 28223373 — intervention group
Group type: EXPERIMENTAL
Intervention: NICU-based interventions (including cognitive behavioral therapy)
Number of subjects: 12
Study 28223373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy interventions
Number of subjects: 12
Study 28223373 — intervention group
Group type: EXPERIMENTAL
Intervention: NICU-based interventions
Number of subjects: 12
Study 23946295 — intervention group
Group type: EXPERIMENTAL
Intervention: Children United with Buddies (CUB) intervention
Number of subjects: 37
Study 23946295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 23280223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/d for 12 days)
Number of subjects: 406
Study 23280223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 20147572 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 30 mg
Number of subjects: 24
Study 20147572 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 4000 mg
Number of subjects: 24
Study 20147572 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 400 mg
Number of subjects: 24
Study 20147572 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid 1500 mg
Number of subjects: 24
Study 20147572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19931753 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-assisted subcutaneous infusion (EASI) with 1-mL injection of 150 U of human recombinant hyaluronidase, followed by 250 mL D5NS infusion.
Number of subjects: 20
Study 19931753 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous (IV) access with 20-gauge IV placement and 250-mL maximal-rate IV bolus of normal saline.
Number of subjects: 20
Study 16412720 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 209
Study 16412720 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 209
Study 12941059 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 16
Study 12941059 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 16
Study 12941059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10864908 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF gene transfer
Number of subjects: 0
Study 9059944 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of inactivated hepatitis A vaccine (25 Units) at 0 and 6 months (group A)
Number of subjects: 105
Study 9059944 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of inactivated hepatitis A vaccine (25 Units) at 0, 2, and 6 months (group B)
Number of subjects: 105
Study 9059944 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 105
Study 1376903 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial synchronous pacing (DDD)
Number of subjects: 17
Study 1376903 — intervention group
Group type: COMPARATOR
Intervention: Activity rate modulated ventricular pacing (VVI,R)
Number of subjects: 17
Study 3891616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation (2.5 g t.i.d.)
Number of subjects: 13
Study 3891616 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no tyrosine supplementation)
Number of subjects: 13
Study 31122717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity inspiratory muscle training (5 weeks, 6 times per week, 5 sets of 10 repetitions, initial load 50% progressing to 70% of maximum inspiratory pressure)
Number of subjects: 25
Study 31122717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 29582077 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette users
Number of subjects: 1357
Study 29582077 — intervention group
Group type: COMPARATOR
Intervention: nonusers
Number of subjects: 1357
Study 29582077 — intervention group
Group type: EXPERIMENTAL
Intervention: intervention patients (free tobacco treatment)
Number of subjects: 1357
Study 29582077 — intervention group
Group type: COMPARATOR
Intervention: control patients (treatment recommendations)
Number of subjects: 1357
Study 26748872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 15
Study 26748872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25285695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursestring closure
Number of subjects: 122
Study 25285695 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary closure
Number of subjects: 122
Study 22424519 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 657
Study 22424519 — intervention group
Group type: COMPARATOR
Intervention: AVR
Number of subjects: 657
Study 20143466 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TCF (docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2) per day for days 1‐14)
Number of subjects: 70
Study 20143466 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery (Control)
Number of subjects: 70
Study 17911462 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 21
Study 16086601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine/pseudoephedrine
Number of subjects: 36
Study 16086601 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 36
Study 11966889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy with PGE2 measurement
Number of subjects: 79
Study 11805612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sygen® treatment (specific dosage and duration not mentioned)
Number of subjects: 760
Study 9922519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mérieux vaccine, 0.1 ml
Number of subjects: 600
Study 9922519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokio vaccine, 0.1 ml
Number of subjects: 600
Study 9922519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mérieux vaccine, 0.05 ml
Number of subjects: 600
Study 9922519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokio vaccine, 0.05 ml
Number of subjects: 600
Study 7921529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 9
Study 7921529 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (5 mg)
Number of subjects: 9
Study 7921529 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 9
Study 3394886 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment for 6 weeks
Number of subjects: 0
Study 3394886 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 0
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR-plus-mirtazapine combination
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-plus-escitalopram combination
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall odds ratio
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy odds ratio
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-plus-mirtazapine combination odds ratio
Number of subjects: 665
Study 30135556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-plus-escitalopram combination odds ratio
Number of subjects: 665
Study 28454823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) plus oxygen
Number of subjects: 78
Study 28454823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen alone)
Number of subjects: 78
Study 26363573 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior plating
Number of subjects: 37
Study 26363573 — intervention group
Group type: COMPARATOR
Intervention: Anteroinferior plating
Number of subjects: 37
Study 23224032 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 104
Study 23224032 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 104
Study 21198725 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20
Study 21198725 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 20
Study 18451387 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weekly intra-articular injections of sodium hyaluronate
Number of subjects: 660
Study 18451387 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weekly intra-articular injections of sodium hyaluronate followed by two weekly intra-articular injections of saline solution
Number of subjects: 660
Study 18451387 — intervention group
Group type: COMPARATOR
Intervention: Five weekly intra-articular injections of saline solution
Number of subjects: 660
Study 16824849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GPIIb/IIIa blockade
Number of subjects: 6010
Study 16824849 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus planned GPIIb/IIIa blockade
Number of subjects: 6010
Study 16824849 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional drug use
Number of subjects: 6010
Study 16824849 — intervention group
Group type: COMPARATOR
Intervention: Randomization to bivalirudin
Number of subjects: 6010
Study 16824849 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional GPIIb/IIIa inhibitor
Number of subjects: 6010
Study 16824849 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 6010
Study 12585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 12585985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11128891 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of patient information
Number of subjects: 50
Study 9035467 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Cp)
Number of subjects: 43
Study 9035467 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) - Hypocalemic patients (CLH)
Number of subjects: 43
Study 9035467 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) - Normocalemic patients (CLN)
Number of subjects: 43
Study 1552035 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 51
Study 1552035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29638007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental anxiety
Number of subjects: 3500
Study 27999852 — intervention group
Group type: COMPARATOR
Intervention: High-Protein Caloric Restriction (HP; n=12)
Number of subjects: 26
Study 27999852 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein Caloric Restriction combined with Resistance Training (HP+RT; n=14)
Number of subjects: 26
Study 26289163 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic seton drainage with oral 6-mercaptopurine (6MP) for one year
Number of subjects: 0
Study 26289163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF medication with 6MP for one year (seton removal after six weeks)
Number of subjects: 0
Study 26289163 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancement plasty after eight weeks of seton drainage (under four months anti-TNF and 6MP for one year)
Number of subjects: 0
Study 26289163 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 0
Study 23048177 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard smoking cessation intervention (individual counseling and nicotine replacement therapies)
Number of subjects: 100
Study 23048177 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation intervention
Number of subjects: 100
Study 23048177 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapies
Number of subjects: 100
Study 20500849 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hemiarthroplasty (HA)
Number of subjects: 80
Study 20500849 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study 19422672 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge-shaped, bedwide, viscoelastic foam cushion
Number of subjects: 162
Study 19422672 — intervention group
Group type: COMPARATOR
Intervention: Ordinary pillow
Number of subjects: 162
Study 16713840 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-arm radial gutter splint
Number of subjects: 118
Study 16713840 — intervention group
Group type: COMPARATOR
Intervention: Sugar tong splint
Number of subjects: 118
Study 16294574 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric membrane dressing (polymem)
Number of subjects: 50
Study 16294574 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic ointment and dry clean dressing (DCD)
Number of subjects: 50
Study 11238259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg
Number of subjects: 785
Study 11238259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg
Number of subjects: 785
Study 9231873 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's recalled pain intensity after 1 day
Number of subjects: 55
Study 9231873 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's recalled pain intensity after 1 week
Number of subjects: 55
Study 9231873 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 55
Study 9231873 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, general memory ability, and pain coping strategies
Number of subjects: 55
Study 7970434 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point arterial sampling with N-isopropyl-p-[123I]-iodoamphetamine (123I-IMP)
Number of subjects: 14
Study 7970434 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsphere method (for comparison)
Number of subjects: 14
Study 3685071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 10
Study 3685071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment avoidance in the intuition condition
Number of subjects: 0
Study 31038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment anxiety in the intuition condition
Number of subjects: 0
Study 31038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment avoidance in the deliberation condition
Number of subjects: 0
Study 31038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment anxiety in the deliberation condition
Number of subjects: 0
Study 29462471 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptive extraction of the deciduous canine
Number of subjects: 67
Study 27852905 — intervention group
Group type: EXPERIMENTAL
Intervention: APM
Number of subjects: 341
Study 27852905 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 341
Study 24449819 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial stem cell injection (TESI) with mesenchymal stem cells
Number of subjects: 30
Study 21950372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75mg-300mg twice a day)
Number of subjects: 31
Study 21950372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21950372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 31
Study 20560884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed ETT
Number of subjects: 70
Study 20560884 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed ETT
Number of subjects: 70
Study 18489451 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from community nurses within 30 days of hospital discharge
Number of subjects: 166
Study 18489451 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 166
Study 16273751 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract stimulation
Number of subjects: 0
Study 16273751 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 0
Study 16273751 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct His bundle stimulation
Number of subjects: 0
Study 16273751 — intervention group
Group type: COMPARATOR
Intervention: Apical right ventricular stimulation
Number of subjects: 0
Study 12681871 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (100 microg) every 4 hours for a maximum of two doses
Number of subjects: 102
Study 12681871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10382948 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF starting on day 8
Number of subjects: 30
Study 10382948 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF starting on day 15
Number of subjects: 30
Study 9124979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome administered by slow intravenous infusion in a daily dose of 2 to 4 g every 12 hours depending on the disease severity.
Number of subjects: 22
Study 9124979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome therapy for exacerbated severe chronic purulent bronchitis.
Number of subjects: 22
Study 9124979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome treatment for mucoviscidosis.
Number of subjects: 22
Study 1829078 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin and ceftriaxone combination therapy (arm A)
Number of subjects: 71